Pakistan successfully tests ballistic missile Shaheen-II

Agencies

May 23, 2019

Islamabad, Nov 23: Pakistan Thursday successfully test-fired surface-to-surface ballistic missile Shaheen-II, capable of hitting targets as far as 1,500 kilometers away, bringing major Indian cities under its range.

The Pakistan Army said in a statement that the launch was aimed at ensuring operational readiness of the Army Strategic Forces Command.

"Shaheen-II Missile is capable of carrying both conventional and nuclear warheads up to a range of 1,500 kilometers. Shaheen-II is a highly capable missile that fully meets Pakistan’s strategic needs towards the maintenance of desired deterrence stability in the region," the Army said.

It said that the launch, having its impact point in the Arabian Sea, was witnessed by Director General Strategic Plans Division, Commander Army Strategic Forces Command, senior officers from the Army Strategic Forces Command, scientists and engineers of the strategic organizations.

Chairman Joint Chiefs of Staff Committee and Services Chiefs congratulated the scientists and engineers on the conduct of successful launch.

President Arif Alvi and Prime Minister Imran Khan have also congratulated scientists on their achievement, the statement said.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

AstraZeneca to withdraw Covid-19 vaccine globally as demand dips after admitting side effects

News Network

May 8,2024

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic.

The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe.

"As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.

The firm's application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.

London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.

Comments